Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Oct 2020
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms PEARL
- Sponsors Centocor
- 23 Sep 2020 Results of pooled analysis of data pooled from 4 studies ( CADMUS, CADMUS-JR, LOTUS and PEARL) extrapolating pharmacodynamic effects of Ustekinumab from Adults to Pediatrics, presented at the 2020 American College of Clinical Pharmacology Annual Meeting
- 31 Aug 2020 Results of pooled analysis (of data from CADMUS, CADMUS JR, LOTUS and PEARL) extrapolating pharmacodynamic effects from adults to pediatrics published in the Clinical Pharmacology and Therapeutics
- 01 Sep 2011 Results published in the Journal of Dermatological Science.